AstraZeneca - Brilinta: better than Exanta?

AstraZeneca has been lifted by clinical results indicating its antiplatelet drug Brilinta outperformed Sanofi-Aventis/Bristol-Myers Squibb's Plavix - currently the world's second biggest-selling medicine - in a phase III trial.

The results of the PLATO study showed that in patients with acute coronary syndrome Brilinta (ticagrelor) was more effective than Plavix (clopidogrel) in preventing serious cardiovascular events such as vascular death and non-fatal myocardial infarction and stroke.

“PLATO should prove to be a transforming trial that launches Brilinta as a key product,” broker Neophytou wrote in a note. “The efficacy advantage in a head-to-head trial against incumbent mega-blockbuster Plavix should provide a boost to sentiment,” he said.

More

Oh, and more on Exanta